TEVA officer sells 10,679 shares at $36

TEVA PHARMACEUTICAL INDUSTRIES LTD Chief Accounting Officer Amir Weiss reported an open-market sale of 10,679 Ordinary Shares on May 6, 2026 at $36.00 per share.

Accepted by SEC EDGAR 05/07/2026 - 04:03 PM EDT

Filing Impact

(Neutral)

Filing Sentiment

(Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

TEVA PHARMACEUTICAL INDUSTRIES LTD Chief Accounting Officer Amir Weiss reported an open-market sale of 10,679 Ordinary Shares on May 6, 2026 at $36.00 per share. After this transaction, he directly holds 20,016 Ordinary Shares, which may be represented by American Depositary Shares on a one-for-one basis.

Insider Trade Summary

Net Seller: 10,679 shares

Net Sell 1 txn

Insider Weiss Amir

Role Chief Accounting Officer

Sold 10,679 shs ($384K)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	10,679	$36.00	$384K

Holdings After Transaction: Ordinary Shares — 20,016 shares (Direct)

Footnotes (1)

F1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Key Figures

Shares sold: 10,679 shares Sale price: $36.00 per share Shares held after sale: 20,016 shares

3 metrics

Shares sold 10,679 shares Open-market sale on May 6, 2026

Sale price $36.00 per share Execution price for Ordinary Shares sold

Shares held after sale 20,016 shares Direct ownership following the transaction

Key Terms

open-market sale, Ordinary Shares, American Depositary Shares, Form 4

4 terms

open-market sale financial

"transaction_action":"open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Ordinary Shares financial

"security_title":"Ordinary Shares"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

American Depositary Shares financial

"may be represented by American Depositary Shares, each of which"

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

Form 4 regulatory

"INSIDER FILING DATA (Form 4)"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did TEVA Chief Accounting Officer Amir Weiss report?

Amir Weiss reported an open-market sale of 10,679 TEVA Ordinary Shares. The transaction occurred on May 6, 2026, and was executed at a price of $36.00 per share, according to the Form 4 insider trading report.

At what price did Amir Weiss sell TEVA shares in this Form 4 filing?

He sold 10,679 TEVA Ordinary Shares at $36.00 per share. This price reflects the execution value for the reported open-market sale on May 6, 2026, as disclosed in the Form 4 insider trading report.

How many TEVA shares does Amir Weiss hold after the reported sale?

Following the sale, Amir Weiss directly holds 20,016 TEVA Ordinary Shares. This post-transaction holding is disclosed in the Form 4 and represents his remaining direct ownership after the May 6, 2026 open-market sale.

What type of security did Amir Weiss trade in this TEVA Form 4?

The transaction involved TEVA Ordinary Shares, which the footnote explains may be represented by American Depositary Shares. Each American Depositary Share currently represents one Ordinary Share, linking U.S.-traded ADS units to the underlying Israeli-listed equity.

Was the TEVA insider transaction by Amir Weiss a buy or sell?

The Form 4 shows a sell transaction coded as an open-market sale. It records 10,679 Ordinary Shares sold at $36.00 per share on May 6, 2026, reducing but not eliminating his direct ownership position in TEVA shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Weiss Amir

(Last)

(First)

(Middle)

C/O TEVA PHARMACEUTICAL INDUSTRIES LTD.

124 DVORA HANEVI'A ST.,

(Street)

TEL AVIV

ISRAEL

6944020

(City)

(State)

(Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
TEVA PHARMACEUTICAL INDUSTRIES LTD [ TEVA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Accounting Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/06/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Ordinary Shares⁽¹⁾	05/06/2026		S		10,679	D	$36	20,016	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

	/s/ Dov Berwerk as attorney-in-fact for Amir Weiss	05/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR